These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28056193)

  • 1. Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia.
    Sopper S; Mustjoki S; White D; Hughes T; Valent P; Burchert A; Gjertsen BT; Gastl G; Baldauf M; Trajanoski Z; Giles F; Hochhaus A; Ernst T; Schenk T; Janssen JJ; Ossenkoppele GJ; Porkka K; Wolf D
    J Clin Oncol; 2017 Jan; 35(2):175-184. PubMed ID: 28056193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
    Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS
    Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic changes in the levels of sCD62L and SPARC in chronic myeloid leukaemia patients during imatinib treatment.
    Elkholy MM; Fahmi MW; El-Haggar SM
    J Clin Pharm Ther; 2022 Dec; 47(12):2115-2129. PubMed ID: 36053969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.
    Thielen N; Richter J; Baldauf M; Barbany G; Fioretos T; Giles F; Gjertsen BT; Hochhaus A; Schuurhuis GJ; Sopper S; Stenke L; Thunberg S; Wolf D; Ossenkoppele G; Porkka K; Janssen J; Mustjoki S
    Clin Cancer Res; 2016 Aug; 22(16):4030-8. PubMed ID: 27006491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.
    Defina M; Ippoliti M; Gozzetti A; Abruzzese E; Castagnetti F; Crupi R; Tiribelli M; Breccia M; Salvucci M; Aprile L; Baratè C; Gozzini A; Rosti G; Lauria F; Bocchia M
    Cancer; 2012 Nov; 118(21):5265-9. PubMed ID: 22517301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.
    Rohon P; Porkka K; Mustjoki S
    Eur J Haematol; 2010 Nov; 85(5):387-98. PubMed ID: 20662899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
    Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
    J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nilotinib as a second-line treatment for chronic myeloid leukemia].
    Yamauchi T; Ueda T
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):911-5. PubMed ID: 21677481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment-free remission and immunity in chronic myeloid leukemia.
    Ureshino H
    Int J Hematol; 2021 May; 113(5):642-647. PubMed ID: 33651270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
    Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akkaynak DZ; Dag IM; Ilhan O
    Expert Opin Pharmacother; 2016 Oct; 17(14):1851-8. PubMed ID: 27501474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.
    Chen CI; Koschmieder S; Kerstiens L; Schemionek M; Altvater B; Pscherer S; Gerss J; Maecker HT; Berdel WE; Juergens H; Lee PP; Rossig C
    Leukemia; 2012 Mar; 26(3):465-74. PubMed ID: 21904381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
    Kreutzman A; Juvonen V; Kairisto V; Ekblom M; Stenke L; Seggewiss R; Porkka K; Mustjoki S
    Blood; 2010 Aug; 116(5):772-82. PubMed ID: 20413659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
    Deremer DL; Ustun C; Natarajan K
    Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib restores expression of CD62L in BCR-ABL-positive cells.
    Fruehauf S; Topaly J; Schad M; Paschka P; Gschaidmeier H; Zeller WJ; Hochhaus A; Ho AD
    J Leukoc Biol; 2003 May; 73(5):600-3. PubMed ID: 12714574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
    Quintás-Cardama A; Kantarjian H; Shan J; Jabbour E; Abruzzo LV; Verstovsek S; Garcia-Manero G; O'Brien S; Cortes J
    Cancer; 2011 Nov; 117(22):5085-93. PubMed ID: 21523765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
    Wolff NC; Ilaria RL
    Blood; 2001 Nov; 98(9):2808-16. PubMed ID: 11675355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.
    de Lavallade H; Khoder A; Hart M; Sarvaria A; Sekine T; Alsuliman A; Mielke S; Bazeos A; Stringaris K; Ali S; Milojkovic D; Foroni L; Chaidos A; Cooper N; Gabriel I; Apperley J; Belsey S; Flanagan RJ; Goldman J; Shpall EJ; Kelleher P; Marin D; Rezvani K
    Blood; 2013 Jul; 122(2):227-38. PubMed ID: 23719297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.